Search Results: (30 results)

We are conducting a fully-online research study to learn more about how genes affect your risk of breast cancer. No office visit is required. Participants provide consent online, answer questions online about their health and medical history, and provide DNA via a saliva sample using a pre-paid mailer through the mail. In return for participation, study participants may receive information about their genetic ancestry for free.

CAR-T therapy is a type of immunotherapy that uses the patient's own immune cells in order to treat their cancer. With CAR-T therapy, the immune cells are removed from the blood and enhanced in the lab to improve their ability to kill cancer cells. The goal of this clinical trial is to learn the safety and effectiveness of an experimental CAR-T combination known as CLBR001+ABBV-461 for treating people with metastatic breast cancer. Another goal is to learn the best dose of this combination for treating metastatic breast cancer. 

This study is testing a new targeted therapy, sacituzumab tirumotecan, given alone or with the immunotherapy Keytruda (pembrolizumab) to treat metastatic, triple-negative breast cancer (TNBC). Keytruda is an immunotherapy that is FDA approved to treat TNBC. The goal of the study is to learn how well sacituzumab tirumotecan can cause tumors to shrink or disappear and how long that response lasts.

This clinical trial is studying two different immunotherapy approaches for people with endometrial cancer that has come back after treatment (recurrent). It focuses on tumors that have a biomarker called mismatch repair deficiency, (dMMR or MMR-D) or microsite instability high (MSI-High). These biomarkers are often found in cancers that respond to immunotherapy.

Prostate cancer is very common among male Veterans. Current screening tests, like the PSA blood test, can find cancer early but can also lead to unnecessary testing and treatment. This study will use genetic testing to see if they can determine which men are at higher risk for serious prostate cancer and which men are at low risk and can avoid unnecessary biopsies. Participants will have testing that looks for gene mutations that may increase the risk for prostate cancer.

This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.

This trial will evaluate the optimal dose, safety and effectiveness of an investigational drug called E7386 given together with a targeted therapy called lenvatinib.

This study is looking at whether using a shorter type of MRI known as bpMRI (biparametric MRI) in combination with PSA tests in men who are at high risk of developing prostate cancer will improve prostate cancer screening and lead to earlier detection. 

This research study is enrolling prostate cancer patients who plan to undergo surgery to have their prostate removed (radical prostatectomy) and whose cancer has one of the listed gene mutations: ATM, BRCA1, BRCA2, CHEK2, PALB2, RAD51B, RAD51C, RAD51D, RAD54L2, BARD1, FANCA or BRIP1.

This clinical trial is studying whether the combination of two targeted therapies, abemaciclib (Verzenio) and a new targeted therapy  ZEN003694 (also known as ZEN-3694) can be given together safely and what dose should be used in future studies.

This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.

The study will determine whether the study medicine mevrometostat can delay or stop the growth of metastatic prostate cancer. Mevrometostat is thought to work by blocking the abnormal EZH2 activity in cells, which may help prevent or delay hormone therapy resistance and cancer growth and progression.

The nonprofit organization, Facing Our Risk of Cancer Empowered (FORCE) is working with the Autistic Self Advocacy Network (ASAN) to learn about people’s needs for information, support and services related to breast health, breast cancer risk and screening. The information will be collected through an online survey. There are two parts to this survey; 1) a short eligibility questionnaire, and 2) a full survey. 

The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations. 

This study will explore the decision making surrounding hormone replacement therapy (HRT) in individuals aged 35-50 with a BRCA1, BRCA2, PALB2, RAD51C, RAD51D genetic mutation who have undergone risk-reducing bilateral salpingo-oophorectomy (removed both tubes and ovaries) to lower cancer risk.

This phase II trial evaluates how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.

This study is looking at whether people with ovarian cancer do better when they take the drug olaparib (also called Lynparza) for one year or for two years after finishing chemotherapy. Some participants in the study may also get another medicine called bevacizumab (Avastin) along with olaparib. You may be able to join this study if you have stage 3 or 4 ovarian cancer and either a BRCA1 or BRCA2 gene change, or a certain tumor marker called HRD.

This research study will test whether higher doses of radiation therapy are safe and effective for people with locally advanced pancreatic cancer. 

This study will look at how often routine MRI scans detect abnormal findings in people with inherited mutations in BRCA1, BRCA2, ATM, and PALB2, who are undergoing pancreatic cancer screening. Researchers want to learn how often MRI and endoscopic ultrasound (EUS) yield abnormal results, and how frequently they find pancreatic cancer or precancer. The study will also review the rate of procedures like biopsies and surgeries among participants. 

PREVAIL is a patient-choice study where African American men with prostate cancer or with a strong family history of cancer can choose to either view a pretest genetic education video before having genetic testing or meet with a genetic counselor before genetic testing.

Survey for people diagnosed with lung, liver, pancreatic or thyroid cancer

EvoPAR-BR01 is studying two investigational drugs as first-line treatment for HER2-negative, HR-positive, metastatic breast cancer in people with an inherited or tumor mutation in BRCA1, BRCA2 or PALB2. Saruparib is a new PARP1 inhibitor (a type of targeted therapy). Camizestrant is an estrogen receptor degrader (a type of hormonal therapy). The study will look at different combinations of treatments to learn which combination leads to the best survival and fewest side effects. 

This study is looking at the effectiveness of a technology-based information and coaching and support program for Asian American women who have been diagnosed with breast cancer.

This study's goal is to understand the experience of Asian patients at least 18 years of age who received genetic test results within the past two years.

The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor. 

This study team wants to understand the experiences of LGBTQIA+ caregivers supporting people with cancer, and what interventions or services could fill their needs and support their health.

This study will examine mindfulness training to improve mental health and well-being in younger breast cancer survivors, also known as “HEAL-ABC.” This trial is currently enrolling young breast cancer survivors who have elevated symptoms associated with depression.

The Li-Fraumeni Syndrome Biobank (LFSBB) study is a biobank that collects specimens such as blood and other biomedical samples for individuals who have Li-Fraumeni Syndrome (LFS), unaffected relatives, and household members.

The purpose of this study is to find out if a medication called eRapa can help slow down the formation of polyps in people with Familial Adenomatous Polyposis (FAP).

SHAREonline compares two brief educational interventions conducted by videoconference to learn if they help women age 19-49 manage sexual function changes after cancer treatment.